Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362633152> ?p ?o ?g. }
- W4362633152 endingPage "194" @default.
- W4362633152 startingPage "185" @default.
- W4362633152 abstract "Purpose Sinonasal tumours are rare diseases with poor prognosis. Multimodal approach including surgery is widely used, although no standard therapy has been established in prospective trials. This study assessed activity and safety of an innovative integration of multimodality treatment—induction chemotherapy (ICT), surgery and radiotherapy (RT)—modulated by histology and response to ICT. Methods Patients with untreated, operable sinonasal tumours with selected histotypes (squamous cell carcinoma, intestinal-type adenocarcinoma, sinonasal undifferentiated and neuroendocrine carcinoma, olfactory neuroblastoma) were enrolled in a single-arm, phase II, multicenter clinical trial. Patients were treated with up to 5 ICT cycles, whose regimen was selected according to histotype, followed either by curative chemo-RT for pts with ≥80% reduction of initial tumour diameter or surgery and adjuvant (chemo)RT. Photon and/or proton/carbon ion-based RT was employed according to the disease site and stage. Primary end-point was 5-year progression-free survival (PFS), secondary end-points were overall survival (OS), ICT objective response rate (ORR) per RECIST 1.1 and safety. Results Thirty-five patients were evaluable for primary end-point. Fourteen patients (40%) were treated with definitive (CT)RT and 20 (57%) underwent surgery. Five-year PFS was 38% (95% confidence interval [CI], 21–69), with a median PFS of 26 months. Five-year OS was 46% (95% CI, 28–75), with a median OS of 36 months. Three-year PFS—OS for pts achieving PR/CR versus stable disease (SD)/PD to ICT were 49.8–57% versus 43.2–53%, respectively. Three-year PFS for patients achieving major volumetric partial response (≥80% reduction of initial tumour volume, major partial volumetric response [mPRv]) versus non-mPRv were 82% versus 28% and 3-year OS were 92% versus 36% (p value 0.010 and 0.029, respectively). The ORR to ICT was 54% and 60% across all histotypes and in the sinonasal undifferentiated carcinoma (SNUC) subpopulation, respectively, with 6/15 SNUCs (40%) achieving mPRv. Conclusion Treatment of advanced sinonasal cancer with histology-driven ICT followed by (CT)RT in responsive patients was feasible. Overall, these findings suggest a possible role of ICT as the primary approach in newly diagnosed, resectable sinonasal tumours—especially SNUC—to select patients with favourable prognosis. Histology heterogeneity limits generalisation of trial results." @default.
- W4362633152 created "2023-04-07" @default.
- W4362633152 creator A5011828547 @default.
- W4362633152 creator A5013780610 @default.
- W4362633152 creator A5017363293 @default.
- W4362633152 creator A5018624121 @default.
- W4362633152 creator A5021152425 @default.
- W4362633152 creator A5022002290 @default.
- W4362633152 creator A5024490839 @default.
- W4362633152 creator A5026992541 @default.
- W4362633152 creator A5027508264 @default.
- W4362633152 creator A5029020197 @default.
- W4362633152 creator A5043177846 @default.
- W4362633152 creator A5047193688 @default.
- W4362633152 creator A5053003166 @default.
- W4362633152 creator A5061232025 @default.
- W4362633152 creator A5067081443 @default.
- W4362633152 creator A5067540429 @default.
- W4362633152 creator A5073202790 @default.
- W4362633152 creator A5081945327 @default.
- W4362633152 creator A5085886527 @default.
- W4362633152 date "2023-07-01" @default.
- W4362633152 modified "2023-09-29" @default.
- W4362633152 title "The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours" @default.
- W4362633152 cites W1638528055 @default.
- W4362633152 cites W1707497420 @default.
- W4362633152 cites W1966988323 @default.
- W4362633152 cites W2018567163 @default.
- W4362633152 cites W2019039483 @default.
- W4362633152 cites W2019607817 @default.
- W4362633152 cites W2021250817 @default.
- W4362633152 cites W2024076011 @default.
- W4362633152 cites W2036571998 @default.
- W4362633152 cites W2064303197 @default.
- W4362633152 cites W2080193946 @default.
- W4362633152 cites W2088002408 @default.
- W4362633152 cites W2092741167 @default.
- W4362633152 cites W2110876229 @default.
- W4362633152 cites W2126438085 @default.
- W4362633152 cites W2169715257 @default.
- W4362633152 cites W2181068196 @default.
- W4362633152 cites W2604574111 @default.
- W4362633152 cites W2765121185 @default.
- W4362633152 cites W2906096025 @default.
- W4362633152 cites W2907165378 @default.
- W4362633152 cites W2909610788 @default.
- W4362633152 cites W2966941627 @default.
- W4362633152 cites W3004526002 @default.
- W4362633152 cites W3087076946 @default.
- W4362633152 cites W3127159130 @default.
- W4362633152 cites W3138402207 @default.
- W4362633152 cites W3187855361 @default.
- W4362633152 cites W4283025610 @default.
- W4362633152 doi "https://doi.org/10.1016/j.ejca.2023.03.033" @default.
- W4362633152 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37164774" @default.
- W4362633152 hasPublicationYear "2023" @default.
- W4362633152 type Work @default.
- W4362633152 citedByCount "1" @default.
- W4362633152 countsByYear W43626331522023 @default.
- W4362633152 crossrefType "journal-article" @default.
- W4362633152 hasAuthorship W4362633152A5011828547 @default.
- W4362633152 hasAuthorship W4362633152A5013780610 @default.
- W4362633152 hasAuthorship W4362633152A5017363293 @default.
- W4362633152 hasAuthorship W4362633152A5018624121 @default.
- W4362633152 hasAuthorship W4362633152A5021152425 @default.
- W4362633152 hasAuthorship W4362633152A5022002290 @default.
- W4362633152 hasAuthorship W4362633152A5024490839 @default.
- W4362633152 hasAuthorship W4362633152A5026992541 @default.
- W4362633152 hasAuthorship W4362633152A5027508264 @default.
- W4362633152 hasAuthorship W4362633152A5029020197 @default.
- W4362633152 hasAuthorship W4362633152A5043177846 @default.
- W4362633152 hasAuthorship W4362633152A5047193688 @default.
- W4362633152 hasAuthorship W4362633152A5053003166 @default.
- W4362633152 hasAuthorship W4362633152A5061232025 @default.
- W4362633152 hasAuthorship W4362633152A5067081443 @default.
- W4362633152 hasAuthorship W4362633152A5067540429 @default.
- W4362633152 hasAuthorship W4362633152A5073202790 @default.
- W4362633152 hasAuthorship W4362633152A5081945327 @default.
- W4362633152 hasAuthorship W4362633152A5085886527 @default.
- W4362633152 hasConcept C126322002 @default.
- W4362633152 hasConcept C141071460 @default.
- W4362633152 hasConcept C168563851 @default.
- W4362633152 hasConcept C203092338 @default.
- W4362633152 hasConcept C2776611710 @default.
- W4362633152 hasConcept C2776694085 @default.
- W4362633152 hasConcept C2779984678 @default.
- W4362633152 hasConcept C2781413609 @default.
- W4362633152 hasConcept C31760486 @default.
- W4362633152 hasConcept C509974204 @default.
- W4362633152 hasConcept C71924100 @default.
- W4362633152 hasConceptScore W4362633152C126322002 @default.
- W4362633152 hasConceptScore W4362633152C141071460 @default.
- W4362633152 hasConceptScore W4362633152C168563851 @default.
- W4362633152 hasConceptScore W4362633152C203092338 @default.
- W4362633152 hasConceptScore W4362633152C2776611710 @default.
- W4362633152 hasConceptScore W4362633152C2776694085 @default.
- W4362633152 hasConceptScore W4362633152C2779984678 @default.
- W4362633152 hasConceptScore W4362633152C2781413609 @default.